Skip to main content
. 2020 Sep 29;22(11):2056–2064. doi: 10.1002/ejhf.1987

Figure 2.

EJHF-1987-FIG-0002-c

Potassium levels in patients allocated to sacubitril–valsartan or enalapril with or without a mineralocorticoid receptor antagonist (MRA). K+ change at week 80 sacubitril–valsartan vs. enalapril and no MRA: −0.05 (−0.08 to −0.01), P = 0.007. K+ change at week 80 sacubitril–valsartan vs. enalapril and MRA: −0.08 (−0.11 to −0.04), P < 0.001. Sac/Val, sacubitril–valsartan.